(Exidavnemab)Biosimilar Reference Antibody-GS40254

货号：GS40254

Exidavnemab is an investigational monoclonal antibody being developed as a novel disease-modifying treatment for neuronal synucleinopathies, specifically Multiple System Atrophy (MSA) and Parkinson's disease (PD). It functions as a targeted immunotherapeutic agent designed to engage with and promote the clearance of pathological alpha-synuclein (α-synuclein) aggregates, a hallmark proteinopathy central to these neurodegenerative diseases. By binding to specific forms of misfolded α-synuclein, exidavnemab aims to facilitate their removal, potentially slowing or halting the underlying neurodegenerative process, rather than merely alleviating symptoms.